Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
Sabrina HeynckesKaram DakaPamela FrancoAnnette GaebeleinJan Hendrik FrenkingRoberto Doria-MedinaIrina MaderDaniel DelevOliver SchnellDieter Henrik HeilandPublished in: BMC cancer (2019)
Our results suggest that TMZ therapy leads to a down-regulation of PD-L1 in primary GBM cells. These results support the clinical findings where PD-L1 is significantly reduced in recurrent GBMs. If the target is diminished, it may also lead to impaired efficacy of PD-1/PD-L1 inhibitors such as nivolumab.